Clinical indications for aldosterone blockade
| Definite |
| • Reduces mortality in chronic heart failure and post-myocardial infarction LV dysfunction |
| • Reduces blood pressure in virtually all hypertensives as both primary and add on treatment |
| Probable |
| • Reduces target organ damage (alone or in addition to ACE inhibitors) |
| –left ventricular hypertrophy in hypertension |
| –microalbuminuria including diabetics |
| Future possibilities |
| • Renoprotective in early renal disease |
| • Reduces cerebral damage in cerebrovascular disease |
| • Reduces cardiovascular events in HOPE/EUROPA type vascular patients (in addition to ACE inhibitors) |